University of Sussex
Browse
New regulation-Rosemann.pdf (1.2 MB)

New regulation for clinical stem cell research in China: expected impact and challenges for implementation

Download (1.2 MB)
journal contribution
posted on 2023-06-08, 23:47 authored by Achim Rosemann, Margaret Sleeboom-FaulknerMargaret Sleeboom-Faulkner
On August 22, 2015 the Chinese National Health and Family Planning Commission (NHFPC, the former Ministry of Health, MOH) have issued the long awaited “draft” regulation on clinical research and applications that involve human stem cells [1] [2] [3]. In China, regulation usually starts out as a draft (??) or trial regulation (??). A draft regulation should be regarded as valid as formal regulation, but it is flexible enough to leave space for change. The document announces the central elements of a regulatory foundation for the clinical translation of stem cell-based medicinal products and procedures. What does China’s future regulation for clinical stem cell trials look like? What challenges can be expected with regard to its implementation? And what impacts will the regulation have for domestic researchers, clinics and corporations in China and at an international level?

Funding

Bionetworking in Asia: Biomaterials and Cell Bank Regimes; ERC; 283219

Bionetworking in Asia: Patient Recruitment & Therapy Practices; ESRC; ES/I018107/1

History

Publication status

  • Published

File Version

  • Published version

Journal

Regenerative Medicine

ISSN

1746-0751

Publisher

Future Medicine

Issue

1

Volume

11

Page range

5-9

Department affiliated with

  • Anthropology Publications

Full text available

  • Yes

Peer reviewed?

  • Yes

Legacy Posted Date

2015-12-21

First Open Access (FOA) Date

2016-08-16

First Compliant Deposit (FCD) Date

2016-08-16

Usage metrics

    University of Sussex (Publications)

    Categories

    No categories selected

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC